Why the study?
As life expectancy in Duchenne muscular dystrophy improves, cardiac causes of death are increasing, and despite available treatments, the prognosis for dystrophic heart disease remains poor.
As respiratory care improves survival in Duchenne muscular dystrophy, dilated cardiomyopathy is emerging as a leading cause of mortality, highlighting the need for novel, mutation-specific, and combined therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Dystrophin deficiency drives DMD myocyte loss via sarcolemma instability; leaves open costamere-targeted therapies for prospective validation.
Florczyk et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: